Tvardi Therapeutics, Inc. (TVRD) Stock Forecast
TVRD analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.22 / 5 from 9 analysts
- Price target
- $9.25 average of analyst targets
- Upside to target
- +815.8% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.51
- 52-week range
- $1.00 – $6.17
TVRD analyst ratings
9 analystsNumber of analysts at each rating.
TVRD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TVRD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.57 | −$1.06 | −$0.28 | −$0.59 | +3.2% | 8 |
| Current fiscal year (2026) | −$2.30 | −$3.02 | −$1.60 | −$2.46 | +6.5% | 8 |
| Next fiscal year (2027) | −$2.24 | −$4.52 | −$0.51 | −$2.30 | +2.7% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TVRD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
TVRD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TVRD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.54 | −$0.53 | −$0.59 | −$0.57 | −$0.57 | +6.4% | 2 up · 0 down |
| Current fiscal year (2026) | −$2.39 | −$2.34 | −$2.35 | −$2.30 | −$2.30 | −3.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.89 | −$2.73 | −$2.37 | −$2.24 | −$2.24 | −22.5% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TVRD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TVRD beat in 4 of 12.
What analysts expect from TVRD
9 analysts cover Tvardi Therapeutics; their consensus rating is buy (4.22 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.25, 815.8% above the latest close of $1.01. Analysts expect earnings of −$2.30 per share for 2026, +6.5% from a year earlier. For 2027 the average estimate is −$2.24 per share. Tvardi Therapeutics beat the EPS estimate in 4 of the last 12 quarters.
Related: TVRD income statement, TVRD key metrics, TVRD chart. See the TVRD stock overview for the latest quote and news.
TVRD forecast FAQ
What is Tvardi Therapeutics's price target?
The average analyst price target for Tvardi Therapeutics is $9.25, 815.8% above the latest close of $1.01.
Is Tvardi Therapeutics a buy, hold or sell?
Of 9 analysts covering Tvardi Therapeutics, 5 rate it a strong buy, 2 a buy, 1 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tvardi Therapeutics's EPS forecast?
Analysts forecast −$2.30 per share for 2026 (range −$3.02 to −$1.60); for 2027 the estimate is −$2.24.
When does Tvardi Therapeutics report earnings?
Tvardi Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.51.
Does Tvardi Therapeutics usually beat earnings estimates?
Tvardi Therapeutics reported EPS at or above the analyst estimate in 4 of the last 12 quarters.